纽瑞克斯制药
NRIX
24.42
-0.53
-2.12%
纽瑞克斯制药
US · NRIX
#2679 按市值排名
上市于 2020
24.42
-0.53
-2.12%
实时 - 追踪5344个代码 - 心跳于95秒前
· 2026-10-16 18:18
✦ 量化股权信号 计算方式说明
增持
- 机构持股总比例上升了0.3个百分点。
机构持股
- 机构持股比例
- 114.25% +0.29pp
- 机构数量
- 250
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund53.95%
Hedge Fund34.56%
VC/PE Fund16.50%
Public Company7.14%
Private Company1.16%
Individual/Insider0.93%
Insurance Company0.43%
Government Pension Fund0.22%
Sovereign Wealth Fund0.18%
主要股东 截至 2026-06-30
BlackRock
8.45% · 8.77M 股
Vestal Point Capital, LP
7.76% · 8.05M 股
Deep Track Capital, LP
7.45% · 7.74M 股
Rubric Capital Management LP
6.96% · 7.23M 股
Perceptive Advisors LLC
5.33% · 5.54M 股
FMR
5.28% · 5.48M 股
T. Rowe Price Group, Inc.
5.24% · 5.44M 股
Vanguard Capital Management, LLC
4.99% · 5.18M 股
Morgan Stanley
4.53% · 4.70M 股
State Street Global Advisors
4.51% · 4.68M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 24次买入 · 26次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Arthur Sands | Chief Executive Officer | 0.73% |
| Gwenn Hansen | Chief Scientific Officer | 0.11% |
| Johannes Van Houte | Chief Financial Officer | 0.04% |
| David Lacey | Independent Chairperson | 0.03% |
| Julia Gregory | Independent Director | 0.01% |
| Christine Ring | General Counsel | 0.01% |
| Judith Reinsdorf | Independent Director | -- |
| Roy Baynes | Member of Medical Advisory Board | -- |
| Lori Kunkel | Independent Director | -- |
| Paul Silva | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-01 | Christine Ring | General Counsel | Derivative Exercise and Sale | -5,786 | $8.72–23.19 |
| 2026-09-01 | Christine Ring | General Counsel | Derivative Exercise and Sale | -5,787 | $8.72–26.64 |
| 2026-08-31 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -1,452 | $1.86–25.47 |
| 2026-08-04 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -4,356 | $1.86–25.00 |
| 2026-08-03 | Johannes Van Houte | Chief Financial Officer | Automatic Disposition | -4,761 | $23.89–24.65 |
| 2026-08-03 | Gwenn Hansen | Chief Scientific Officer | Automatic Disposition | -4,111 | $23.87–24.64 |
| 2026-08-02 | Christine Ring | General Counsel | Automatic Disposition | -10,802 | $23.05 |
| 2026-08-02 | Christine Ring | General Counsel | Derivative Exercise and Sale | -5,787 | $8.72–23.05 |
| 2026-07-29 | Johannes Van Houte | Chief Financial Officer | Derivative Exercise and Sale | -2,845 | $23.38 |
| 2026-07-29 | Johannes Van Houte | Chief Financial Officer | Derivative Exercise and Retained | +7,335 | -- |
| 2026-07-29 | Christine Ring | General Counsel | Derivative Exercise and Sale | -3,847 | $23.38 |
| 2026-07-29 | Christine Ring | General Counsel | Derivative Exercise and Retained | +6,333 | -- |
| 2026-07-29 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -3,847 | $23.38 |
| 2026-07-29 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Retained | +6,333 | -- |
| 2026-07-01 | Christine Ring | General Counsel | Derivative Exercise and Sale | -11,008 | $1.86–23.56 |
| 2026-06-24 | Christine Ring | General Counsel | Derivative Exercise and Sale | -28,935 | $7.26–20.06 |
| 2026-06-24 | Gwenn Hansen | Chief Scientific Officer | Automatic Disposition | -5,394 | $20.00 |
| 2026-06-01 | Christine Ring | General Counsel | Automatic Disposition | -4,726 | $16.60 |
| 2026-06-01 | Christine Ring | General Counsel | Derivative Exercise and Sale | -3,422 | $1.86–16.60 |
| 2026-05-14 | Julia Gregory | Independent Director | Other Derivative Acquisition | +31,250 | $15.86 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 18:18:36 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
纽瑞克斯制药 讨论区 0 条评论